HomeNewsNeuroscienceDepression

  • FDA approves Alembic’s generic drug for Major Depressive Disorder

    • June 12, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Esketamine displays positive Ph 3 trial outcomes for Depression

    • June 3, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Allergan acquires depression compound from Aptinyx

    • May 24, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • 33 percent more people suffer from Depression as compared to 2013, new research finds

    • May 11, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Esketamine improves outcomes in Treatment-Resistant Depression patients, new Phase 3 data shows

    • May 8, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • NDA submitted for Brexanolone in Postpartum Depression by Sage Therapeutics

    • April 24, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Intranasal Esketamine improves Depression symptoms as per latest clinical trial results

    • April 21, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
SPEAK TO AN EXPERT